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The aim of this study was to investigate the protective effect of cordymin on diabetic osteopenia in alloxan-induced diabetic
rats and the possible mechanisms involved. The diabetic rats received daily intraperitoneal injection with cordymin (20, 50, and
100mg/kg/day) for 5 weeks. Cordymin could restore the circulating blood glucose, glycosylated hemoglobin (HbA1c), serum
alkaline phosphatase (ALP), tartrate resistant acid phosphatase (TRAP), and insulin levels in a dose-dependent manner. Also, the
treatment of diabetic rats with cordymin could partially reverse the 𝗽 cells death and decrease the total antioxidant status (TAOS)
in the diabetic rats. The results may directly and indirectly account for the possible mechanism of the beneficial effect of cordymin
on diabetic osteopenia, which was confirmed with the increased bone mineral content (BMC) and bone mineral density (BMD) in
diabetic rats (𝑃 < 0.05). All those findings indicate that cordymin may play a protective role in diabetic osteoporosis.
1. Introduction
An increasing number of diabetic patients are affected
by chronic complications, such as cardiovascular disease,
kidney disease, diabetes erectile dysfunction, and diabetic
osteoporosis [1–4]. The association between diabetes and
decreased BMD has been confirmed in adults (Figure 1),
and BMD appears to be decreased in both the spine and
hip in diabetic patients [5, 6]. These associations may be
related to increased risk of fractures in individuals with
diabetes, increased risk of diabetes mellitus in individuals
with osteopenia, or both. Growing evidence from clinical
studies indicates that osteopenia always leads to an increased
incidence of bone fracture and a delay in healing of bone
fractures and affects the quality of life in diabetic patients [7].
Therefore,searchingforeffectivedrugswhichcancontrolthe
developmentofdiabeticosteopeniaisofgreatsignificancefor
patients with diabetic osteopenia.
Cordyceps sinensis ( C S )h a sb e e nu s e da sat o n i cf o r
longevity, endurance, and vitality for thousands of years
by the Chinese. Many studies have shown that CS regu-
lates insulin sensitivity [8] and decreases plasma cholesterol
levels [9]. The effect of Cordyceps sinensis on osteoporosis
h a db e e ns t u d i e di no u rf o r m e rp a p e r[ 10]. So we herein
hypothesize that Cordyceps sinensis will be beneficial in
preventingosteopeniaindiabetesandinfluencingthelonger-
term course of glycemic control. We undertook the present
study to ascertain if cordymin, a peptide purified from the
medicinal mushroom Cordyceps sinensis, could be accounted
f o rt h ep u t a t i v eb e n e fi c i a le ff e c to fC So nd i a b e t i co s t e o p e n i a
in diabetic rats.
2. Material and Methods
2.1. Preparation of Cordymin. Cordyceps sinensis was col-
lected from Qing Hai, China. Cordymin was prepared by the
way introduced by Wong et al. [11]. Briefly, dried fruiting
bodies of Cordyceps sinensis (100g) were homogenized in
liquid nitrogen with a pestle, extracted in distilled water2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Possible mechanisms through which diabetic conditions increase the risk of osteoporotic fractures (AGEs: advanced glycation end
products).
and centrifuged. To the resulting supernatant, ammonium
acetate buffer (pH 4.5) was added until a final concentration
of 20mM was attained. The sample was loaded on an SP-
Sepharose column. The adsorbed fraction was eluted with
1M NaCl in 20mM ammonium acetate buffer (pH 4.5), then
dialyzed against distilled water, and lyophilized. Then it was
dissolvedin20mMNH4OAcbuffer(pH4.5)andappliedona
M o noScol umnandel u tedwi ththesameb uffer .Thefractio n
containingcordyminwasconcentratedandthenpurifiedona
Superdex75columninthesamebuffer .Thesinglepeakeluted
constituted purified peptide designated as cordymin.
The molecular mass determination of cordymin was
analyzed by means of SDS-PAGE and Matrix-assisted
laser desorption ionization time-of-flight mass spectrome-
try (MALDI-TOFMS) in an Applied Biosystems 4700 Pro-
teomics Analyzer.
Th eN - t e r m i n a la m i n oa c i ds e q u e n c eo fc o r d y m i nw a s
analyzed by means of Automated Edman Degradation using
aHewlettPackard1000Aproteinsequencerequippedwithan
HPLC system.
2.2. Experimental Design. Thirty Sprague-Dawley male rats
were divided into 5 groups (𝑛=1 0 ) at random. The rats in
the diabetic and cordymin treatment groups were fasted for
10h and intraperitoneally injected with 75mg/kg of alloxan
to induce diabetes; the remaining 10 control rats were also
fasted for 10h and injected with 0.9% saline. Forty-eight
hours after the injection, blood glucose was >16mmol/L and
urineglucosewas>+indicatingthatdiabeteswassuccessfully
inducedintherats.Theratsinthecordymintreatmentgroup
were intraperitoneally injected with cordymin (20, 50, and
100mg/kg/day) for 5 weeks, and the other 2 groups of rats
were intraperitoneally injected with saline (6mL/kg/day).
Thebodyweightsoftheanimalswererecordedweeklyduring
the experimental period.
At the end of the experimental period, the animals were
fasted overnight (18h) and then sacrificed by decapitation,
a ndthebloodwascollectedtobecen trifugeda t3000rp mf o r
20min, and the clear serum was separated for biochemical
analysis. The pancreas was dissected out and placed in 10%
buffered formalin, and the liver was dissected out for the
m e a s u r e m e n to ft o t a la n t i o x i d a n ts t a t u s( T A O S ) .F e m u r s
w e r ed i s s e c t e da n dfi l l e di np h y s i o l o g i c a ls a l i n ea n ds t o r e d
at −20
∘C for measurement of total bone mineral content
(BMC) and bone mineral density (BMD) by Dual-energy X-
ray absorptiometry.
2.3. Biochemical Methodology. The blood glucose was
analyzed with a Glucometer-4 (Bayer) and HbA1c with
t h eH b A 1 cA p p a r a t u s( V a r i a n tI I ,B i o - R a dL a b o r a t o r i e s ) .
Serum insulin level was determined with an enzyme-
linkedimmunosorbantassay(ELISA)kit (NanjingJiancheng
BioengineeringCo.Ltd.,China).Serumalkalinephosphatase
(ALP)andtartrateresistantacidphosphatase(TRAP)activity
were determined by nitrophenol-based method as described
by Bessy et al. [12]a n dG o d k a r[ 13], respectively.
2.4. Estimation of the Damaged Pancreatic 𝗽 Cells. The
pancreatic tissues were embedded in paraffin blocks after
formalinfixation.Paraffinsectionswerecutat4𝜇mthickness
and were deparaffinized in xylene twice for 5min and then
were rehydrated with the graded ethanol. The sections were
examined after hematoxylin and eosin (H&E) staining.
2.5. Estimation of the Total Antioxidant Activity. The total
antioxidant status (TAOS) of hepatic tissue was determined
by the way introduced by Laight et al. [14]. The increase in
absorbance at 405nm was measured by using a microplate
reader (Shanghai Xunda Medical Technology Inc., China).Evidence-Based Complementary and Alternative Medicine 3
2.6. Estimation of Bone Mineral Content (BMC) and Bone
Mineral Density (BMD). The left femur and L-4 vertebra
w e r em i n e r a l i z e da tt h et e m p e r a t u r eo f6 2 0
∘Cf o r4 8ha n d
weighed. The mineralized bones were dissolved in 6M HCl,
and then calcium content in the bone mineral content was
assayed by a colorimetric method. BMD was calculated by
BMC of the measured area.
3. Results
3.1. Effect of Cordymin on the Body Weights of the Diabetic
Osteopenic Rats. The body weights of the hyperglycemic rats
induced by alloxan are presented in Figure 2.Th eini tialbod y
weights of the rats were similar between groups. The body
weightsofthealloxan-induceddiabeticratsweresignificantly
lower than that of the control rats. Contrasted with the
diabetic group, the body weights of rats in cordymin-treated
group were increased gradually 21 days later (𝑃 < 0.05, 𝑃<
0.01).
3.2.E ff ecto fCo r d ym i no nt h eB loodG l uc o sea n dH bA1cLeve ls
of the Diabetic Osteopenic Rats. The results of blood glucose
from hyperglycemic rats induced by alloxan are presented
in Table 1. The serum glucose levels of the saline-treated
diabetic rats were significantly higher than that of other rats
(𝑃 < 0.05). Treatment with cordymin at 50mg/kg and
100mg/kg significantly lowered the serum glucose level in
diabeticrats(𝑃 < 0.05).Meanwhile,cordymincoulddecrease
the concentration of HbA1c in plasma of alloxan-induced
hyperglycemic group 5 weeks later (𝑃 < 0.01),as shown in
Table 1.
3.3. Effect of Cordymin on Serum Insulin of the Diabetic
Osteopenic Rats. As shown in Table 2,t h el e v e l so fs e r u m
insulin elevated after administration of cordymin100 (𝑃<
0.05).However ,thesameresultsdidnotoccurinothergroups
throughout the total duration of the study.
3.4. Effect of Cordymin on Plasma Enzyme of the Diabetic
Osteopenic Rats. In the present study, significant increase
in ALP and TRAP levels, two bone formation mark-
ers, was observed in alloxan-induced hyperglycemic group
(Table 3). On the contrary, cordymin at 100mg/kg signifi-
c a n t l yd e c r e a s e dA L Pa n dT R A Pl e v e l s( 𝑃 < 0.01)i nd i a b e t i c
rats, while cordymin at 50mg/kg and 20mg/kg had little
influenceonthetwoboneformationmarkersindiabeticrats.
3.5. Effect of Cordymin on the Damaged Pancreatic 𝗽 Cells.
Histopathological evaluation revealed severe 𝗽 cells death in
t h ed i a b e t i cr a t s( F i g u r e3(a)). In contrast, such loss of cells
was not seen in the islet cells of the control rats (Figure 3(b)).
The 𝗽 cells of the rats fed with cordymin −100 were partially
recovered (Figure 3(c)).
3 . 6 .E ff e c to fC o r d y m i no nT o t a lA n t i o x i d a n tA c t i v i t yo ft h e
Diabetic Osteopenic Rats. We measured TAOS activity as an
indirect indication of the formation of O2
− and other oxidant
species. This index was increased in the diabetic groups
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Figure 2: Effects of cordymin on the weekly average body weights.
Values are means ± SEM, 𝑛=1 0 .
∗Different from alloxan group
𝑃 < 0.05;
∗∗different from alloxan group, 𝑃 < 0.01.
Table 1: Effect of cordymin on blood glucose and HbA1c levels in
alloxan-diabetic osteopenic rats.
Different groups Blood glucose
(mmol/L)
Results of HbA1c
(%)
Alloxan-treated 21.0 ± 2.0 10.8 ± 0.20
Cordymin100-treated 13.2 ± 3.0
∗ 8.0 ± 0.30
∗
Cordymin50-treated 19.2 ± 3.2
∗ 10.0 ± 0.25
Cordymin20-treated 18.8 ± 2.5 9.8 ± 0.30
Control group 6.0 ± 1.5 4.8 ± 0.21
Values are shown as means ± SEM, 𝑛=1 0 .
∗𝑃 < 0.05 versus alloxan group.
Table 2: Effect of cordymin on serum insulin level in alloxan-
diabetic osteopenic rats.
Different groups Serum insulin (𝜇U/mL)
Alloxan-treated 4.4 ± 1.1
Cordymin100-treated 8.4 ± 0.2
∗
Cordymin50-treated 6.1 ± 1.1
Cordymin20-treated 5.5 ± 1.0
Control group 8.5 ± 1.2
Values are shown as means ± SEM, 𝑛=1 0 .
∗𝑃 < 0.05 versus alloxan group.
Table3:Effectsofcordyminonplasmaenzymesinalloxan-diabetic
osteopenic rats.
Different groups TRAP level (uM) ALP level (mM)
Alloxan-treated 0.83 ± 0.11 7.20 ± 0.10
Cordymin100-treated 0.46 ± 0.03
∗ 4.00 ± 0.03
∗
Cordymin50-treated 0.50 ± 0.01 5.90 ± 0.05
Cordymin20-treated 0.70 ± 0.05 6.30 ± 0.05
Control group 0.20 ± 0.11
∗ 3.25 ± 0.12
Values are shown as means ± SEM, 𝑛=1 0 . ∗𝑃 < 0.05 versus alloxan group.
induced by alloxan in comparison with the control group. In
contrast, the TAOS activities of both the cordymin −100 and
cordymin−50groupswerelowerthanthoseofdiabeticgroup
(𝑃 < 0.05 and 𝑃 < 0.01)( F i g u r e4).4 Evidence-Based Complementary and Alternative Medicine
(a) (b) (c)
Figure 3: Islet cell death and replication represented by hematoxylin-eosin. The islet cells of diabetic rats of alloxan treatment (a) showed
extensive cell lysis, representing loss of plasma membrane with condensed nuclei and dissolved cytoplasm in wide intercellular spaces. In
contrast, the islet cell of cordymin100-fed rat (b) was partly recovered. The islet cell of control rat was (c).
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Figure4:Effectofcordyminontotalantioxidant.Activityvaluesare
shown as means ± SEM.
∗𝑃 < 0.05 versus alloxan group;
∗∗𝑃 < 0.01
versus alloxan group.
Table 4: Effects of cordymin on bone mineral content.
Different groups
Total bone
mineral content
(mg)
Calcium content
(mg/g)
Control group 309.05 ± 8.16
a 389.65 ± 10.22
a
Alloxan-treated 263.26 ± 5.63
b 326.25 ± 9.66
b
Cordymin100-treated 316.11 ± 6.20
a 443.21 ± 12.23
a
Cordymin50-treated 316.11 ± 6.20
a 443.21 ± 12.23
a
Cordymin20-treated 316.11 ± 6.20
a 443.21 ± 12.23
a
The different letters in the same column indicate a statistical difference (𝑃<
0.05).
3.7. Effect of Cordymin on BMC and BMD. The BMC in
the examined bones of the diabetic groups was significantly
reduced compared to the results obtained for the controls.
The administration of cordymin100 and cordymin50 to the
diabetic animals increased significantly the BMC in the
examined bones when compared to the diabetic group
(Table 4). Meanwhile, cordymin at 100mg/kg significantly
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Figure 5: Effect of cordymin on bone mineral density (BMD).
Values are shown as means ± SEM.
∗𝑃 < 0.05 versus alloxan group.
increased the femur BMD in diabetic rats (𝑃 < 0.05)
(Figure 5).
4. Discussion
The wide spread chronic disorder of diabetes mellitus
adversely affects multiple organ systems including bones.
One of the serious skeletal complications in bones is
osteoporotic fractures due to weakened bone strength. The
relationship between diabetes and osteoporosis is widely
reported[15–17].Ratmodelsofdiabeticosteopeniahavecon-
tributed significantly to the pathophysiologic understanding
oftheseclinicalchallengeswithregardtoboneturnover,bone
regeneration,and pharmacologictherapies [18,19]. However,
the animal model of diabetic osteopenia was usually induced
with streptozotocin (STZ), and fewer models were induced
with an intravenous dose of alloxan. In the present study, we
investigated the effects of cordymin on diabetic osteoporosis
using the alloxan-induced diabetic rat model.
Alloxan diabetes has been commonly utilized as an ani-
mal model of insulin-dependent diabetes mellitus (IDDM).
Alloxan produces selective cytotoxicity in pancreatic 𝗽 cellsEvidence-Based Complementary and Alternative Medicine 5
throughthegenerationofreactiveoxygenspeciesresultingin
r e d u c e ds y n t h e s i sa n dr e l e a s eo fi n s u l i n[ 20]. In the present
study, we examined the antidiabetogenic effect of cordymin
bymonitoringthe𝗽cellsnumber,andisletmasswasassessed
by morphometry on immunostained tissue sections. The
𝗽 cells death and alteration of islet cell population were
prominent in the alloxan-induced diabetic rats (Figure 1(a)).
In addition, alloxan-induced type 1 diabetes reduced bone
quality. Alloxan-treated rats showed a decrease in femoral
BMCandBMDcomparedtonormalcontrolrats(Table4and
Figure5).Itdemonstratedthesignificantassociationbetween
diabetes and osteoporosis.
The present study was performed to investigate the effec-
tiveness of cordymin on diabetic osteoporosis. Cordymin-
treated rats, indeed, exhibited the recovery of 𝗽 cells. It is
consistent with the results of cordymin treatment on insulin
levels. At the same time, BMC and BMD in diabetic rats
treated with cordymin increased when compared to the
diabetic rats. Therefore, the beneficial effect of cordymin
on pancreatic tissue and its capability of improving serum
insulin level might be, at least in part, responsible for the
protective effect of cordymin on diabetic osteopenia in the
present study.
Hyperglycemia is able to trigger increased oxidative
stress, which has been considered to be involved in the
pathogenesisofdiabeticbonedisorders[21].Cordymincould
lower the blood glucose and HbA1c levels, which have been
shown to trigger decreased TAOS in diabetic rats. Therefore,
the effect of cordymin on diabetic osteopenia in the present
study might also be realized indirectly through lowering
the concentration of serum glucose, which subsequently
triggered a lower extent of oxidative stress in diabetic rats.
Serum alkaline phosphatase (ALP) is a noncollagenous
protein secreted by osteoblast, which is essential for bone
mineralization [22]. Increased ALP level in serum has been
observed in conditions such as rapid bone loss [23]a n d
fracture risk [24, 25]. Tartrate resistant acid phosphatase
( T R A P )i ss e c r e t e db yo s t e o c l a s t sd u r i n gb o n er e s o r p t i o n ,
andserumTRAPactivitycorrelateswithresorptiveactivityin
disordersofbonemetabolism.Inthepresentstudy,cordymin
significantly decreased ALP and TRAP levels commonly
usingboneremodelingmarkers.Itsuggestedthatthepotency
of cordymin is due to decrease of ALP activity and TRAP
activity in diabetic rats.
In conclusion, the present study showed for the first time
that administration of cordymin has significant effects in rat
model of diabetic osteopenia, including dose-dependently
restoring the circulating blood glucose, HbA1c, ALP, TRAP,
and insulin levels. The beneficial effect of cordymin on
diabetic osteopenia might be directly through lowering ALP
and TRAP activity and indirectly through recovery of 𝗽 cells
and lowering the concentration of serum glucose, which
subsequently triggered a lower extent of oxidative stress in
diabetic rats.
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